Replies to post #795 on Arrayit Corporation (ARYC)

[MikeCr]

Thanks for posting this Jan 7th, 2010 Arrayit news release. I had read it but had forgotten about it. As you point out, it is a very good press release. It should have made a big splash in the media but it only caused a ripple. Just like the previous news relesase which Arrayit says "that press information distributed by Arrayit on December 9th, somehow fell through the cracks."

I did a google search on the Arrayit Jan 7th PR title and got 2 hits: encyclopedia.com and bloombergnews.com.
I did a similar google search on the title of the PR of the CA-125 new approach to old test study released Thursday and got hundreds of hits in all the major media outlets and many minor ones.

Why this difference in coverage if Ovadx is a much better product which would be available this year or next and the study approach is more of the same CA-125 tests to be available in 2015 at the earliest.

Some possibilites come to mind:

1) the Arrayit release says "Researchers at a major cancer research institute have worked for six years to identify more than 100 biomarkers unique to ovarian cancer." The center's name is not mentioned and Arrayit itself is a very little known company. The study PR mentions the name of the doctors (including the doctor who invented the CA-125 test)and the hospital doing the research. Which story would you trust more?

2) AP and Reuters picked up and distributed the study story to all media outlets: TV, radio, magazines, newspapers, blogs, etc. which published and discussed the story, The story quoted medical specialists praising the test, stories of women participating in the study, some clinical data and description of what's up ahead with the clinical studies. Arrayit PR's did not do any of the above.

3) CA-125 test already has sales of over $2 billion a year and the maker of the test , Fujirebio Diagnostics, would benefit from the success of the study (more tests, more money). They have plenty of money for top-notch PR machinery. As to Arrayit they have little money and their PR dept. so far is not too effective.

Let's hope that Arrayit steps up to the PR plate when it announces the details of OvaDx screening and monitoring test after completion of their independent trials and the FDA application. The PR can not afford to fall through the cracks again.

[General_Sevier]

What I was thinking was more along the lines of detailing current C-125, Vermillion, the one that we discussed a couple weeks ago and this most recent one. Detail the use, the process, the targets, etc. Even go into detail on the numbers used by Vermillion and the other one to get regulatory approval, etc. The press is lazy and so is much of Wall Street. ARYC cleary is. So spend some time and put this together and publicize it.

Heck, if I were them, I'd consider putting it together and emailing it to every reporter that covered the other story. I saw the MD Anderson story on two local channels.

[ehwest]

Using 100 or so markers should make this test very accurate and coupled with the fact that it will provide a very early warning date is revolutionary. But, until the test results are released, the stock is still a way out speculation.

Some forms of cancer grow so slowly, that the patient will die of other causes before the cancer can cause real harm. Therefore, the test must also be able to detect the aggressiveness of the cancer and help determine if early treatment will benefit the patient. An example of this is prostate cancer. In prostate cancer, the physician can't do much until they determines the aggressiveness of the cancer, which usually is not easy to determine. If a man lives to age 90, over 90% of those men will have some degree of prostate cancer. You can't go around cutting out every man's prostate when they first detect cancer.

I've got a feeling it is the same for ovarian cancer??? Need to do more DD on it.

GLTAL